<i>ASXL1</i> mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO‐defined polycythaemia vera patients

Björn Andréasson(NU Hospital Group), Julia Asp(Sahlgrenska University Hospital), Peter Johansson(Linköping University), Carina Wasslavik(Sahlgrenska University Hospital), Lars Palmqvist(Sahlgrenska University Hospital), Helna Pettersson(NU Hospital Group)

British Journal of Haematology

February 17, 2020

10.1111/bjh.16450

Cited by 12

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

|Journal of Clinical Oncology|2012|461

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

|Blood|2011|340

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

|Journal of Clinical Oncology|2011|244

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

|The Lancet|2023|194

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

|Blood|2014|153